OBJECTIVES: To study anal intraepithelial neoplasia and its associations with anal and cervical human papillomavirus (HPV), cervical neoplasia, host immune status, and demographic and behavioral risk factors in women with and at risk for HIV infection. DESIGN: Point-prevalence analysis nested within a prospective study of women seen at three clinical centers of the Women's Interagency HIV Study. METHODS: In 2001-2003 participants were interviewed, received a gynecological examination, anal and cervical cytology testing and, if abnormal, colposcopy-guided or anoscopy-guided biopsy of visible lesions. Exfoliated cervical and anal specimens were assessed for HPV using PCR and type-specific HPV probing. Logistic regression analyses were performed, and odds ratios (ORs) estimated risks for anal intraepithelial neoplasia. RESULTS: Four hundred and seventy HIV-infected and 185 HIV-uninfected women were enrolled. Low-grade anal intraepithelial neoplasia was present in 12% of HIV-infected and 5% of HIV-uninfected women. High-grade anal intraepithelial neoplasia was present in 9% of HIV-infected and 1% of HIV-uninfected women. In adjusted analyses among HIV-infected women, the risk factors for low-grade anal intraepithelial neoplasia were younger age [OR = 0.59, 95% confidence interval (CI) = 0.36-0.97], history of receptive anal intercourse (OR = 3.2, 95% CI = 1.5-6.8), anal HPV (oncogenic types only OR = 11, 95% CI = 1.2-103; oncogenic and nononcogenic types OR = 11, 95% CI = 1.3-96), and cervical HPV (oncogenic and nononcogenic types OR = 3.5, 95% CI = 1.1-11). In multivariable analyses among HIV-infected women, the only significant risk factor for high-grade anal intraepithelial neoplasia was anal HPV infection (oncogenic and nononcogenic types OR = 7.6, 95% CI = 1.5-38). CONCLUSION: Even in the era of highly active antiviral therapy, the prevalence of anal intraepithelial neoplasia was 16% in HIV-infected women. After controlling for potential confounders, several risk factors for low-grade anal intraepithelial neoplasia differed from risk factors for high-grade anal intraepithelial neoplasia.
OBJECTIVES: To study anal intraepithelial neoplasia and its associations with anal and cervical human papillomavirus (HPV), cervical neoplasia, host immune status, and demographic and behavioral risk factors in women with and at risk for HIV infection. DESIGN: Point-prevalence analysis nested within a prospective study of women seen at three clinical centers of the Women's Interagency HIV Study. METHODS: In 2001-2003 participants were interviewed, received a gynecological examination, anal and cervical cytology testing and, if abnormal, colposcopy-guided or anoscopy-guided biopsy of visible lesions. Exfoliated cervical and anal specimens were assessed for HPV using PCR and type-specific HPV probing. Logistic regression analyses were performed, and odds ratios (ORs) estimated risks for anal intraepithelial neoplasia. RESULTS: Four hundred and seventy HIV-infected and 185 HIV-uninfectedwomen were enrolled. Low-grade anal intraepithelial neoplasia was present in 12% of HIV-infected and 5% of HIV-uninfectedwomen. High-grade anal intraepithelial neoplasia was present in 9% of HIV-infected and 1% of HIV-uninfectedwomen. In adjusted analyses among HIV-infectedwomen, the risk factors for low-grade anal intraepithelial neoplasia were younger age [OR = 0.59, 95% confidence interval (CI) = 0.36-0.97], history of receptive anal intercourse (OR = 3.2, 95% CI = 1.5-6.8), anal HPV (oncogenic types only OR = 11, 95% CI = 1.2-103; oncogenic and nononcogenic types OR = 11, 95% CI = 1.3-96), and cervical HPV (oncogenic and nononcogenic types OR = 3.5, 95% CI = 1.1-11). In multivariable analyses among HIV-infectedwomen, the only significant risk factor for high-grade anal intraepithelial neoplasia was anal HPV infection (oncogenic and nononcogenic types OR = 7.6, 95% CI = 1.5-38). CONCLUSION: Even in the era of highly active antiviral therapy, the prevalence of anal intraepithelial neoplasia was 16% in HIV-infectedwomen. After controlling for potential confounders, several risk factors for low-grade anal intraepithelial neoplasia differed from risk factors for high-grade anal intraepithelial neoplasia.
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: P A Fox; J E Seet; J Stebbing; N Francis; S E Barton; S Strauss; T G Allen-Mersh; B G Gazzard; M Bower Journal: Sex Transm Infect Date: 2005-04 Impact factor: 3.519
Authors: Joel M Palefsky; Elizabeth A Holly; Jimmy T Efirdc; Maria Da Costa; Naomi Jay; J Michael Berry; Teresa M Darragh Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Carrie M Nielson; Roberto Flores; Robin B Harris; Martha Abrahamsen; Mary R Papenfuss; Eileen F Dunne; Lauri E Markowitz; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: Nancy A Hessol; Sharon Pipkin; Sandra Schwarcz; Rosemary D Cress; Peter Bacchetti; Susan Scheer Journal: Am J Epidemiol Date: 2007-03-06 Impact factor: 4.897
Authors: Nancy A Hessol; Elizabeth A Holly; Jimmy T Efird; Howard Minkoff; Kathleen M Weber; Teresa M Darragh; Robert D Burk; Howard D Strickler; Ruth M Greenblatt; Joel M Palefsky Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Cecile D Lahiri; Minh Ly Nguyen; C Christina Mehta; Marina Mosunjac; Talaat Tadros; Elizabeth R Unger; Mangalathu S Rajeevan; Jendai Richards; Ighovwerha Ofotokun; Lisa Flowers Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Tracy A Battaglia; Christine M Gunn; Molly E McCoy; Helen H Mu; Amy S Baranoski; Elizabeth Y Chiao; Lisa A Kachnic; Elizabeth A Stier Journal: Womens Health Issues Date: 2015-08-04